Inotuzumab ozogamicin binds CD22 on B cells, is internalized, and releases calicheamicin, which binds the DNA minor groove to cause double‑strand breaks and apoptosis. The DNA minor groove is the intracellular payload target, not the selective antigen determining which cells are killed.